Trial Profile
A Methodology Study to Assess the Ability of a Randomised, Double Blind, Placebo Controlled, Crossover Trial Design in Spinal Cord Injury Patients With Pain of Neuropathic Origin to Detect Improvement in Pain Endpoints Using Pregabalin as a Benchmark Compound
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2021
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary)
- Indications Neuropathic pain
- Focus Therapeutic Use
- Sponsors Pfizer; Viatris Inc
- 19 Sep 2009 New trial record